Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 2, 2007

Ranbaxy’s Generic Hypertension Drug Given Go-Ahead

  • Ranbaxy Laboratories (RLL) received approval for its generic version of AstraZeneca’s hypertension drug. "This will further expand our product portfolio of affordable generic alternatives to the brand in the treatment of cardiovascular disorders,” says Jim Meehan, vp of sales and marketing for Ranbaxy Pharmaceuticals, a wholly owned subsidiary of RLL.

    Atenolol tablets USP, 25 mg, 50 mg, and 100 mg were deemed bioequivalent and have the same therapeutic effect as Tenormin®. Besides hypertension, Atenolol is also indicated for the long-term management of patients with angina pectoris due to coronary atherosclerosis and the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality.

    The company reports that according to IMS data, total annual market sales for Atenolol were $133.6 million. RLL expects to start selling its generic during the first quarter of 2007.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »